Immune responses in patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine

International Journal of Oncology

Volumn 46, Issue 4, 2015, Pages 1699-1709

  Narita, Miwako ^a   Kanda, Tatsuo ^b   Abe, Takashi ^b   Uchiyama, Takayoshi ^a   Iwafuchi, Minami ^a   Zheng, Zhiyin ^b   Liu, Aichun ^b   Kaifu, Tsutomu ^b   Kosugi, Shinichi ^b   Minagawa, Masahiro ^b   Itoh, Kyogo ^c   Takahashi, Masuhiro ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c KURUME UNIVERSITY   (Japan)

Author keywords

Antigenspecific ctl; Cells; ELISPOT; Esophageal cancer; Exosomes; SART1

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; SART1 PEPTIDE PULSED MONOCYTE DERIVED DENDRITIC CELL VACCINE; UNCLASSIFIED DRUG; PEPTIDE; SART1 PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN; TUMOR ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; ENZYME LINKED IMMUNOSPOT ASSAY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; EXOSOME; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; HYPOPHOSPHATEMIA; IMMUNE RESPONSE; IN VITRO STUDY; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TUMOR IMMUNITY; CARCINOMA, SQUAMOUS CELL; CELL CULTURE; CLINICAL TRIAL; DENDRITIC CELL; ESOPHAGEAL NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PROCEDURES;

AGED; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; CELLS, CULTURED; DENDRITIC CELLS; ESOPHAGEAL NEOPLASMS; FEASIBILITY STUDIES; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PEPTIDES; RIBONUCLEOPROTEINS, SMALL NUCLEAR; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 84923088313     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2846     Document Type: Article

References (27)

1. SIEWERT JR and OTT K: Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol 17: 38-44, 2007.
2. LAGERGREN J and LAGERGREN P: Oesophageal cancer. BMj 341: C6280, 2010.
3. PALUCKA K and BANCHEREAU J: Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12: 265-277, 2012.
4. KANTOFF PW, HIGANO CS, SHORE ND, BERGER ER, SMALL EJ, PENSON DF, REDFERN CH, FERRARI AC, DREICER R, SIMS RB, XU Y, FROHLICH MW and SCHELLHAMMER PF; Impact Study Investigators: Sipuleucel-t immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422, 2010.
5. KATO Y: Wt1 peptide pulsed dendritic Cell therapy with activated t lymphocytes therapy for advanced cancers. gan to Kagaku ryoho 37: 2240-2242, 2010 (in japanese).
6. ASAKAGE M, KITAYAMA J, TSUNO NH, KOMURO Y, KAISAKI S, HORI N, NAGAWA H, TSUNO NH, HORI N and TAKAHASHI K: Primary malignant melanoma of the esophagus treated by esophagectomy and adjuvant dendritic-cell therapy. J gastroenterol 40: 545-546, 2005.
7. UEDA Y, SHIMIZU K, ITOH T, FUJI N, NAITO K, SHIOZAKI A, YAMAMOTO Y, SHIMIZU T, IWAMOTO A, TAMAI H and YAMAGISHI H: Induction of peptide-specifc immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with Mage peptides. jpn-clin Oncol 37: 140-145, 2007
8. KIKUCHI M, NAKAO M, INOUE Y, MATSUNAGA K, SHICHIJO S, YAMANA H and ITOH K: Identifcation of a SART-1-derived peptide capable of inducing Hla-a24-restricted and tumor-specific cytotoxic t lymphocytes. Int J Cancer 81: 459-466, 1999.
9. Y ARITA M, TOCHIKI N, SAITOH A, WATANABE N, KAJI M, SATOH N, YAMAHIRA A, NAKAMURA T, MASUKO M, FURUKAWA T, TOBA K, FUSE I, AIZAWA Y and TAKAHASHI M: Induction of antigen-specifc cytotoxic t lymphocytes by using monocyte-derived DCs trans-fected with in vitro-transcribed Wt1 or Sart1 mr c. Med Oncol 26: 429-436, 2009
10. ZITVOGEL L, CEGNAULT A, LOZIER G, WOLFERS J, FLAMENT E, TENZA D, RICCIARDI-CASTAGNOLI P, L APOSO G and AMIGORENA S: Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes. Nat Med 4: 594-600, 1998.
11. THÉRY C, BOUSSAC M, VÉRON P, RICCIARDI-CASTAGNOLI P, RAPOSO G, T ARIN J and AMIGORENA S: Proteomic analysis of dendritic cell-derived exosomes: A secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 166: 7309-7318, 2001.
12. YAMAHIRA A, NARITA M, NAKAMURA T, WATANABE A, KAJI M, TANIGUCHI T, HASHIMOTO S, FURUKAWA T, TOBA K, AIZAWA Y, KUZUSHIMA K and TAKAHASHI M: Generation of antigen-specifc cytotoxic t lymphocytes using a leukemic plasmacytoid dendritic Cell line as antigen presenting cells. leuk Res 35: 793-799, 2011.
13. FURUKAWA T, KOIKE T, YING W, KISHI K, AOKI S, GOTOH T, HASHIMOTO S, SAITOH H, HANANO M, SHINADA S, et al: Establishment of a new Cell line with the characteristics of a multipotential progenitor from a patient with chronic myelogenous leukemia in early erythroblastic crisis. leukemia 8: 171-180, 1994
14. SHORE ND, MANTZ CA, DOSORETZ DE, FERNANDEZ E, MYSLICKI FA, MCCOY C, FINKELSTEIN SE and FISHMAN MN: Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer. Cancer control 20: 7-16, 2013.
15. FUJIWARA S, WADA H, MIYATA H, KAWADA J, KAWABATA R, NISHIKAWA H, GNJATIC S, SEDRAK C, SATO E, NAKAMURA Y, SAKAKIBARA M, KANTO T, SHIMOSEGAWA E, HATAZAWA J, TAKAHASHI T, KUROKAWA Y, YAMASAKI M, NAKAJIMA K, TAKIGUCHI S, NAKAYAMA E, MORI M and DOKI Y: Clinical trial of the intratumoral administration of labeled Dc combined with systemic chemotherapy for esophageal cancer. J immunother 35: 513-521, 2012.
16. MILANO F and KRISHNADATH KK: Novel therapeutic strategies for treating esophageal adenocarcinoma: The potential of dendritic Cell immunotherapy and combinatorial regimens. Hum Immunol 69: 614-624, 2008.
17. KONO K, IINUMA H, AKUTSU Y, TANAKA H, HAYASHI N, UCHIKADO Y, O OGUCHI T, FUJII H, OKINAKA K, FUKUSHIMA R, MATSUBARA H, OHIRA M, BABA H, NATSUGOE S, KITANO S, TAKEDA K, YOSHIDA K, TSUNODA T and NAKAMURA Y: Multicenter, phase II clinical trial of Cancer vaccination for advanced esophageal Cancer with three peptides derived from novel cancer-testis antigens. J transl Med 10: 141, 2012.
18. THÉRY C, OSTROWSKI M and SEGURA E: Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9: 581-593, 2009
19. HAO S, BAI O, LI F, YUAN J, LAFERTE S and XIANG J: Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic t-lymphocyte responses and antitumour immunity. Immunology 120: 90-102, 2007
20. TAIEB J, CHAPUT N, SCHARTZ N, ROUX S, NOVAULT S, MÉNARD C, GHIRINGHELLI F, TERME M, CARPENTIER A F, DARRASSE-JÈZE G, LEMONNIER F and ZITVOGEL C HEMOIMMUNOTHERAPY OF TUMORS: Cyclophosphamide synergizes with exosome based vaccines. J Immunol 176: 2722-2729, 2006.
21. DAI S, WEI D, WU Z, ZHOU X, WEI X, HUANG H and LI G: Phase II clinical trial of autologous ascites-derived exosomes combined with gM-cSf for colorectal cancer. Mol Ther 16: 782-790, 2008.
22. ESCUDIER B, DORVAL T, CHAPUT N, C NDRÉ F, CABY MP, NOVAULT S, FLAMENT C, LEBOULAIRE C, BORG C, AMIGORENA S, BOCCACCIO C, BONNEROT C, DHELLIN C, MOVASSAGH M, PIPERNO S, O T OBERT T, SERRA V, VALENTE N, LE PECQ JB, SPATZ A, LANTZ R, URSZ ANGEVIN E and ZITVOGEL L: Vaccination of metastatic melanoma patients with autologous dendritic Cell (Dc) derived-exosomes: Results of the frst phase II clinical trial. J Transl Med 3: 10, 2005
23. MORSE MA, GARST J, OSADA T, KHAN S, HOBEIKA A, CLAY TM, VALENTE N, SHREENIWAS R, SUTTON MA, DELCAYRE A, HSU DH, LE PECQ JB and LYERLY HK: A phase II study of dexosome immunotherapy in patients with advanced non-small Cell lung cancer. J transl Med 3: 9, 2005.
24. BERNTSEN A, TREPIAKAS R, WENANDY C, GEERTSEN PF, THOR STRATEN P, ANDERSEN MH, PEDERSEN AT, CLAESSON MH, LORENTZEN T, JOHANSEN JS and SVANE IM: Therapeutic dendritic Cell vaccination of patients with metastatic renal Cell carcinoma: A clinical phase 1/2 trial. J Immunother 31: 771-780, 2008.
25. TREPIAKAS R, BERNTSEN A, HADRUP SR, BJøRN J, GEERTSEN PF, STRATEN P T, ANDERSEN MH, PEDERSEN AE, SOLEIMANI F, LORENTZEN T, JOHANSEN JS and SVANE IM: Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: Results from a phase I/II trial. Cytotherapy 12: 721-734, 2010.
26. SVANE IM, PEDERSEN AE, JOHNSEN H C, NIELSEN D, KAMBY C, GAARSDAL E, NIKOLAJSEN K, BUUS S and CLAESSON MH: Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: Report from a phase II study. Cancer Immunol immunother 53: 633-641, 2004
27. ELLEBAEK E, ENGELL-NOERREGAARD L, IVERSEN TZ, FROESIG TM, MUNIR S, HADRUP SR, ANDERSEN MH and SVANE IM: Metastatic melanoma patients treated with dendritic Cell vaccination, interleukin-2 and metronomic cyclophosphamide: Results from a phase II trial. Cancer Immunol Immunother 61: 1791-1804, 2012.